多发性骨髓瘤的治疗。采用不同美法仑剂量方案的联合化疗。 - Suppr

Suppr

超能文献

Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens.

作者信息

Alexanian R, Haut A, Khan A U, Lane M, McKelvey E M, Migliore P J, Stuckey W J, Wilson H E

出版信息

JAMA. 1969 Jun 2;208(9):1680-5. doi: 10.1001/jama.208.9.1680.

DOI:10.1001/jama.208.9.1680

PMID:5818682

Abstract

摘要

相似文献

Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens.多发性骨髓瘤的治疗。采用不同美法仑剂量方案的联合化疗。

JAMA. 1969 Jun 2;208(9):1680-5. doi: 10.1001/jama.208.9.1680.

Myeloma proteins, Bence Jones proteins and normal immunoglobulins in multiple myeloma.多发性骨髓瘤中的骨髓瘤蛋白、本斯·琼斯蛋白和正常免疫球蛋白

Blood. 1967 Sep;30(3):265-87.

Long-term follow-up and therapy in multiple myeloma.多发性骨髓瘤的长期随访与治疗

Cancer. 1971 Jan;27(1):44-50. doi: 10.1002/1097-0142(197101)27:1<44::aid-cncr2820270108>3.0.co;2-s.

Plasmacytic myeloma. A study of the relationship of survival to various clinical manifestations and anomalous protein type in 112 patients.浆细胞骨髓瘤。112例患者生存与各种临床表现及异常蛋白类型关系的研究。

Am J Med. 1967 Jun;42(6):937-48. doi: 10.1016/0002-9343(67)90074-5.

Multiple myeloma. II. The value of melphalan.

S Afr Med J. 1974 May 18;48(24):1026-8.

Plasma cell myeloma with D-myeloma protein (IgD myeloma).

Am J Med. 1968 Sep;45(3):373-80. doi: 10.1016/0002-9343(68)90071-5.

Multiple myeloma without initial paraproteins.无初始副蛋白的多发性骨髓瘤

Am J Med Sci. 1972 Oct;264(4):267-75. doi: 10.1097/00000441-197210000-00002.

Multiple myeloma. A clinical review.

Med Clin North Am. 1975 Mar;59(2):375-86. doi: 10.1016/s0025-7125(16)32039-9.

[Gamma-D-paraproteinemia. Clinical case contribution based on 2 studies].[γ-D型副蛋白血症。基于两项研究的临床病例贡献]

Schweiz Med Wochenschr. 1967 Feb 11;97(6):170-8.

Plasma cell myeloma: response of melphalan-resistant patients to high-dose intermittent cyclophosphamide.浆细胞骨髓瘤：美法仑耐药患者对大剂量间歇性环磷酰胺的反应

Can Med Assoc J. 1972 Nov 4;107(9):851-5.

引用本文的文献

Revolutions at the frontline of multiple myeloma treatment: lessons and challenges to finding a cure.多发性骨髓瘤治疗前沿的变革：寻找治愈方法的经验与挑战

Front Oncol. 2025 Jun 20;15:1578529. doi: 10.3389/fonc.2025.1578529. eCollection 2025.

The Evolving Landscape in Multiple Myeloma: From Risk Stratification to T Cell-Directed Advanced Therapies.多发性骨髓瘤不断演变的格局：从风险分层到T细胞导向的先进疗法。

Cancers (Basel). 2025 Feb 5;17(3):525. doi: 10.3390/cancers17030525.

Multiple Myeloma: Improved Outcomes Resulting from a Rapidly Expanding Number of Therapeutic Options.多发性骨髓瘤：治疗选择数量迅速增加带来的预后改善

Target Oncol. 2025 Mar;20(2):247-267. doi: 10.1007/s11523-024-01122-4. Epub 2025 Jan 29.

Efficacy and Safety of High-Dose Chemotherapy with Treosulfan and Melphalan in Multiple Myeloma.曲奥舒凡与美法仑大剂量化疗治疗多发性骨髓瘤的疗效与安全性

Cancers (Basel). 2023 May 10;15(10):2699. doi: 10.3390/cancers15102699.

How I treat multiple myeloma in geriatric patients.我如何治疗老年多发性骨髓瘤患者。

Blood. 2024 Jan 18;143(3):224-232. doi: 10.1182/blood.2022017635.

Canadian perspectives in multiple myeloma on the use of steroids in clinical practice based on patient and healthcare provider interviews.基于对患者和医疗服务提供者的访谈，加拿大在多发性骨髓瘤临床实践中使用类固醇的观点。

Front Oncol. 2022 Dec 8;12:1061417. doi: 10.3389/fonc.2022.1061417. eCollection 2022.

DFT study of therapeutic potential of graphitic carbon nitride as a carrier for controlled release of melphalan: an anticancer drug.基于密度泛函理论研究石墨相氮化碳作为美法仑控释载体的治疗潜力：一种抗癌药物。

J Mol Model. 2022 Oct 13;28(11):359. doi: 10.1007/s00894-022-05337-y.

Ann Hematol. 2022 May;101(5):1031-1038. doi: 10.1007/s00277-022-04775-1. Epub 2022 Mar 9.

Tumor Reduction in Multiple Myeloma: New Concepts for New Therapeutics.多发性骨髓瘤中的肿瘤缩小：新疗法的新概念

Front Oncol. 2022 Jan 14;11:800309. doi: 10.3389/fonc.2021.800309. eCollection 2021.

Genome Instability in Multiple Myeloma: Facts and Factors.多发性骨髓瘤中的基因组不稳定：事实与因素

Cancers (Basel). 2021 Nov 26;13(23):5949. doi: 10.3390/cancers13235949.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验